TY - JOUR
T1 - Capturing of the free cysteine residue in the ligand-binding site by affinity labeling of the ORL1 nociceptin receptor
AU - Matsushima, Ayami
AU - Nishimura, Hirokazu
AU - Inamine, Shogo
AU - Uemura, Shiho
AU - Shimohigashi, Yasuyuki
N1 - Funding Information:
This work was supported by grants-in-aid from the Ministry of Education, Culture, Sports, Science, and Technology of Japan to Y.S. (23657078) and A.M. (22600006). This study was also supported in part by Health and Labour Sciences Research Grants to Y.S., for Research on the Risk of Chemical Substances, from the Ministry of Health, Labor, and Welfare of Japan.
PY - 2011/12/15
Y1 - 2011/12/15
N2 - All of the δ, μ, and κ opioid receptors have a free thiol group of the Cys residue in the ligand-binding site, although its functional role is not yet known. In order to examine whether or not a similar Cys is also present in the ORL1 nociceptin receptor, we attempted to identify it by affinity labeling using a specific antagonist peptide. We first treated ORL1-expressing COS-7 cell membrane preparations with the thiol-alkylation reagent N-ethylmaleimide (NEM) to perform a binding assay using [ 3H] nociceptin as a tracer and nociceptin, an ORL1 agonist, or Ac-Arg-Tyr-Tyr-Arg- Ile-Lys-NH 2, a nociceptin/ORL1 antagonist, as a competitor. It was suggested that ORL1 has a free Cys in its ligand-binding site, since the NEM treatment reduced the population of ligand-binding sites. This was further confirmed by affinity labeling using Cys(Npys)-Arg-Tyr-Tyr-Arg-Ile-Lys-NH 2 with the SNpys group that can react with a free thiol group, resulting in the formation of a disulfide bond. This affinity labeling was approximately 23 times more specific than NEM alkylation. The results revealed that the ORL1 nociceptin receptor does contain a free Cys residue in the ligand-binding site.
AB - All of the δ, μ, and κ opioid receptors have a free thiol group of the Cys residue in the ligand-binding site, although its functional role is not yet known. In order to examine whether or not a similar Cys is also present in the ORL1 nociceptin receptor, we attempted to identify it by affinity labeling using a specific antagonist peptide. We first treated ORL1-expressing COS-7 cell membrane preparations with the thiol-alkylation reagent N-ethylmaleimide (NEM) to perform a binding assay using [ 3H] nociceptin as a tracer and nociceptin, an ORL1 agonist, or Ac-Arg-Tyr-Tyr-Arg- Ile-Lys-NH 2, a nociceptin/ORL1 antagonist, as a competitor. It was suggested that ORL1 has a free Cys in its ligand-binding site, since the NEM treatment reduced the population of ligand-binding sites. This was further confirmed by affinity labeling using Cys(Npys)-Arg-Tyr-Tyr-Arg-Ile-Lys-NH 2 with the SNpys group that can react with a free thiol group, resulting in the formation of a disulfide bond. This affinity labeling was approximately 23 times more specific than NEM alkylation. The results revealed that the ORL1 nociceptin receptor does contain a free Cys residue in the ligand-binding site.
UR - http://www.scopus.com/inward/record.url?scp=82255183055&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=82255183055&partnerID=8YFLogxK
U2 - 10.1016/j.bmc.2011.10.024
DO - 10.1016/j.bmc.2011.10.024
M3 - Article
C2 - 22061823
AN - SCOPUS:82255183055
SN - 0968-0896
VL - 19
SP - 7597
EP - 7602
JO - Bioorganic and Medicinal Chemistry
JF - Bioorganic and Medicinal Chemistry
IS - 24
ER -